Business brief
Defense Exports Squeezed by Shekel Strength as Teva Bids for Distressed Biotech
State defense prime Rafael urges FX intervention despite record order backlog, Volkswagen negotiates Iron Dome manufacturing in Germany, and Teva targets distressed neuroscience assets.
Business
European carmakers are turning to Israeli defense partnerships to save idle factories — repurposing auto assembly lines for missile defense production.
BackgroundEuropean automakers face structural headwinds and plant closures due to shifting EV demand and high labor costs. German federal and state leaders are assisting negotiations to repurpose automotive industrial capacity for European defense manufacturing.
- Retooling Osnabruck would convert vehicle assembly lines into military component manufacturing suites, preserving thousands of industrial jobs in Germany.
- Negotiations involve resolving corporate pushback regarding defense manufacturing and objections from Qatar's sovereign wealth fund, which holds a 17% VW stake.
- The partnership reflects rapid integration between Israeli air defense tech and European industrial manufacturing capacity as military spending surges.
Business
Record defense demand is being squeezed by shekel currency strength — setting up friction between state defense primes and central bank exchange rate policy.
BackgroundDomestic military demands accounted for 56% of sales during intense conflict operations, while international exports comprised the remainder. Strengthening shekel exchange rates reduce local currency revenue on long-term foreign currency export contracts.
- Q2 revenue rose 20% in shekel terms to ₪5.6 billion, supported by high demand for Iron Dome and David's Sling interceptors.
- Chairman Yuval Steinitz renewed proposals for a partial initial public offering of Rafael on the Tel Aviv Stock Exchange to fund capital expansion.
- Exporters across the defense sector face tightening profit margins despite record overall order volumes, threatening domestic manufacturing investment.
Business
Teva is using targeted bankruptcy acquisitions to snap up late-stage neuroscience assets — bolstering its higher-margin branded drug portfolio while limiting early-stage R&D risk.
BackgroundTeva CEO Richard Francis has pursued a 'Pivot to Growth' strategy focusing on specialized branded neuroscience and immunology assets rather than legacy generic lines. BioXcel filed for Chapter 11 protection to complete an asset sale under court supervision.
- BXCL501 aims to become the first FDA-approved at-home outpatient treatment for acute neuropsychiatric agitation, opening a potentially lucrative market segment.
- The acquisition expands Teva's branded central nervous system therapeutic pipeline without the high risk and capital expenditure of early-stage clinical development.
- Financial terms remain subject to bankruptcy court auction procedures and final regulatory approval, determining whether competing biopharma buyers submit higher cash bids.
Unlock the full brief
Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.
